VERTEX PHARMACEUTICALS THIRD QUARTER 2026 EARNINGS CALL - CRINETICS PHARMACEUTICALS INC

Financial Performance:

• Total revenue grew 12% year-over-year to approximately $4.2 billion for Q3 2026 (implied from guidance context), with 10% U.S. growth and 16% international growth.
• Revenue contributions: Cystic Fibrosis (CF) generated $3.3B (+8% YoY); Sickle Cell/Beta Thalassemia (Casgevi) generated $99M (+30% sequential); Acute Pain (Jernavix) generated $58M (+18% sequential); Rare Endocrinology (Palsonify) generated $24M (post-acquisition close).
• Non-GAAP gross margin was 85.6% (GAAP 84.7% due to Krenetics step-up amortization); full-year 2026 gross margin guidance remains slightly below 86%.
• Non-GAAP net income was $1.21 billion; Non-GAAP EPS was $4.76.
• Krenetics acquisition added $10M in Q3 revenue and $60M in integration/operating expenses; $41M recorded in acquired IPR&D expense, including a $28M payment to Abcelera.
• Cash and investments ended at $9.8 billion; raised $4.5B in term loans (approx. 4.8% interest) for the acquisition.

Guidance and Future Outlook:

• Raised full-year 2026 total revenue guidance to $13.15–$13.25 billion (up from $13.1–$13.2B), driven by Krenetics ($40–$50M contribution) and continued CF/Heme/Pain/Rare Endo growth.
• Raised full-year non-GAAP operating expense guidance to ~$6.0 billion (up from $5.65–$5.75B) due to $250M in Krenetics integration and operating costs.
• Full-year 2026 non-operating costs estimated at $105M (interest/costs related to Krenetics financing); interest income expected to be $60M lower due to post-acquisition cash deployment.
• Non-GAAP effective tax rate guidance for 2026 remains 19.5–20.5%.
• Targeting >$500M in combined revenue from Casgevi and Jernavix in 2026; Palsonify projected to contribute ~$60M in Q1 2027 alone.

Business Segments and Product Lines:

• Cystic Fibrosis: Olifrec (80% of CF revenue) treats 95% of patients; global sales surpassed $1B YTD. Submissions initiated for ages 2–5; next-gen correctors (VX828, VX581, VX272) in development.
• Heme: Casgevi approved for ages 2–11 in U.S./Gulf/UK; >750 patient initiations worldwide; 100+ quarterly initiations for four consecutive quarters.
• Pain: Jernavix is #1 branded oral analgesic in U.S. (>1.6M treated); 750k prescriptions in Q3 (up 40% sequentially). Phase III for painful diabetic peripheral neuropathy (DPN) enrollment complete, data expected mid-2027.
• Rare Endocrinology: Palsonify (Acromegaly) launched; ~40% brand share among initiators/switchers; Phase III for congenital adrenal hyperplasia (Atumelanant) underway, enrollment target Q1 2027.
• Renal: POVI (povitacicept) for IgA nephropathy awaits PDUFA (Nov 30); Phase III Rainier data published in NEJM. Anaxiplin (AMKD) completed enrollment; interim analysis results expected early 2027 (GFR primary endpoint).

Market and Competitive Landscape:

• CF market: Olifrec achieving sweat chloride levels indistinguishable from healthy carriers in trials; 31 countries now have reimbursement.
• Pain market: Jernavix replacing entrenched opioid/gabapentin habits; 82% managed lives covered by July 2026 Medicare Part D agreements.
• Renal market: POVI differentiates via subcutaneous auto-injector (0.46mL, q4w) vs. weekly/intravenous competitors; nephrologists express strong enthusiasm for BAF inhibitor class.
• Krenetics integration: Palsonify leveraging existing endocrinologist base (3,000 U.S. specialists); 500+ prescribers active within first quarter.

Risks and Challenges:

• Krenetics Integration: $60M in Q3 non-operating/integration costs; ongoing financial impact on margins until PSP (Patient Support Program) sunsets.
• Gross-to-Net Pressure: Jernavix gross-to-net expected to stabilize at 50–60% after mid-2027 PSP sunset; one-time net revenue reset occurred due to Medicare Part D contract shifts.
• Regulatory Uncertainty: Anonymous citizen petition regarding POVI IgG monitoring/dose-hold rules (80% of such petitions are anonymous); FDA approval timeline remains the primary variable for launch.
• Pipeline Risk: Next-gen CF corrector selection pending VX828/VX581/VX272 comparative data; potential need to wait for full data before pivotal advancement.

Management Commentary and Tone:

• Leadership Transition: CFO Charlie Wagner retiring (final call); CEO Reshma Kewalramani praised his legacy; Jonathan Poole (SVP Finance) confirmed as new CFO starting Jan 1, 2027.
• Tone: Highly confident and bullish; management emphasized "excellent commercial results," "strong commercial execution," and "accelerating" pipeline progress.
• Strategic Focus: Explicit pivot from CF-only to a diversified biotech with five commercial pillars (CF, Heme, Pain, Rare Endo, Renal).

Analyst Questions and Answers:

• POVI Monitoring: Reshma clarified that IgG monitoring is based on trial data where 0.5% SAE infection rate was balanced; no opportunistic infections observed; FDA discussions ongoing.
• AMKD (Anaxiplin): "Win" defined as statistically significant GFR improvement (primary endpoint); Phase 2 data (47.6% UACR reduction) and Phase 3 interim results expected to show separation from placebo.
• Manufacturing: Confirmed FDA involvement in continuous manufacturing process for POVI; CMC module submitted in March, no concerns regarding scalability.
• CF Next-Gen: VX828 showed 6.6–9.4 mmol/L sweat chloride reduction vs. Trikafta in FMF patients; company will wait for VX581/VX272 data to select the best candidate.
• Palsonify PSP: Patient Support Program remains active through 2026 to secure access for uncovered patients; revenue growth expected to accelerate as PSP sunsets mid-2027.

Other Key Points:

• Acquisition: Krenetics closed in September; added Palsonify (Acromegaly) as the 8th commercial product and Atumelanant (CAH) to the pipeline.
• Pipeline Updates: VX017 (T1D) dosing began; goal to move to pivotal development next year. Myotonic Dystrophy (VX670) interim results expected end of year. Generalized Myasthenia Gravis (povitacicept) Phase II enrollment complete.
• Capital Deployment: $120M used for share repurchases in Q3; $921M YTD; priority remains innovation and share buybacks.
• Global Reach: POVI launch planned globally; filed for accelerated approval in Saudi Arabia (7,000 patient opportunity) and targeting Europe/Asia submissions post-2-year data.